Lead Product(s) : Elapegademase
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EZN-2279 in Patients With ADA-SCID
Details : EZN-2279 is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Severe Combined Immunodeficiency.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
August 19, 2011
Lead Product(s) : Elapegademase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
